Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Aspen-p
ASPEN BROMOCRIPTINE SCHEDULING STATUS: S4 PROPRIETARY NAME (and dosage form): ASPEN BROMOCRIPTINE 2,5 mg compressed tablet COMPOSITION: Each tablet contains 2,5 mg Bromocriptine PHARMACOLOGICAL CLASSIFICATION: A 21.12 Hormone inhibitors. PHARMACOLOGICAL ACTION: Bromocriptine, an ergot derivative, is a dopaminergic receptor stimulant. Dopamine, a neurotransmitter, has an effect on hypothalamic function, in particular it has an effect on prolactin secretion and can regulate growth hormone secretion. Bromocriptine inhibits the secretion of prolactin by the pituitary. Bromocriptine lowers elevated circulating growth hormone levels in acromegalics. INDICATIONS: 1. Inhibition of lactation Prevention or suppression of puerperal lactation for medical reasons. Bromocriptine is not recommended for the routine suppression of lactation, or for the relief of symptoms of postpartum pain and engorgement, which can be adequately treated with simple analgesics and breast support. 2. Menstrual cycle disorders and female infertility associated with hyperprolactinaemia. 3. Hyperprolactinaemia in men Prolactin-related hypogonadism with loss of libido and impotence. 4. Prolactinomas Conservative treatment of prolactin-secreting pituitary micro-adenomas or macro-adenomas. Prior to surgery to reduce tumour size to facilitate removal or after surgery if prolactin level is still elevated. 5. Certain cases of acromegaly as adjunctive therapy Bromocriptine has been used in a number of specialised units, as an adjunct to surgery and/or radiotherapy, to reduce circulating growth hormone levels in the management of acromegalic patients. 6. Parkinsonism Idiopathic and postencephalitic Parkinson's disease, either in monotherapy or in combination with other anti- Parkinsonian medicines. Bromocriptine may improve tremor, rig Read the complete document